Axon Enterprise, Inc. (NASDAQ:AXON) Shares Acquired by Lindbrook Capital LLC

Lindbrook Capital LLC increased its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 43.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 172 shares of the biotechnology company’s stock after purchasing an additional 52 shares during the period. Lindbrook Capital LLC’s holdings in Axon Enterprise were worth $44,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CWM LLC raised its holdings in shares of Axon Enterprise by 1.8% in the third quarter. CWM LLC now owns 2,669 shares of the biotechnology company’s stock worth $531,000 after acquiring an additional 46 shares during the last quarter. AE Wealth Management LLC raised its stake in Axon Enterprise by 32.4% in the 3rd quarter. AE Wealth Management LLC now owns 1,775 shares of the biotechnology company’s stock valued at $353,000 after purchasing an additional 434 shares during the last quarter. IFP Advisors Inc lifted its holdings in Axon Enterprise by 150.2% in the 3rd quarter. IFP Advisors Inc now owns 618 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 371 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Axon Enterprise by 156.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 2,878 shares of the biotechnology company’s stock worth $573,000 after purchasing an additional 1,754 shares during the last quarter. Finally, Czech National Bank grew its holdings in shares of Axon Enterprise by 47.8% during the third quarter. Czech National Bank now owns 12,282 shares of the biotechnology company’s stock worth $2,444,000 after buying an additional 3,973 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Trading Up 1.3 %

NASDAQ AXON opened at $306.24 on Friday. The firm has a market capitalization of $23.11 billion, a price-to-earnings ratio of 133.15 and a beta of 0.93. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.66 and a current ratio of 3.00. Axon Enterprise, Inc. has a one year low of $175.37 and a one year high of $329.87. The company’s 50 day moving average price is $302.78 and its 200 day moving average price is $260.58.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.29. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. The business had revenue of $432.14 million for the quarter, compared to the consensus estimate of $418.97 million. On average, sell-side analysts predict that Axon Enterprise, Inc. will post 2.44 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on AXON shares. JMP Securities upped their price objective on shares of Axon Enterprise from $250.00 to $285.00 and gave the company a “market outperform” rating in a research note on Tuesday, February 6th. Argus started coverage on Axon Enterprise in a report on Wednesday, March 13th. They set a “buy” rating and a $380.00 price objective on the stock. StockNews.com lowered Axon Enterprise from a “buy” rating to a “hold” rating in a research note on Thursday, March 14th. Barclays raised their price target on Axon Enterprise from $296.00 to $308.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Finally, Robert W. Baird increased their price objective on shares of Axon Enterprise from $260.00 to $300.00 and gave the stock an “outperform” rating in a report on Thursday, February 22nd. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $312.64.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.